IASO Bio's CD20-Targeted In Vivo CAR-T Therapy IASO208 Receives FDA IND Clearance

IASO Bio’s proprietary CD20-targeted in vivo CAR-T therapy, IASO208, has received FDA IND clearance, marking the first China-originated lentiviral vector-based in vivo CAR-T therapy advancement into US Phase 1b trials for relapsed/refractory B-cell non-Hodgkin lymphoma.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.